Prodrug design of phenolic drugs

Current Pharmaceutical Design

Volumn 16, Issue 18, 2010, Pages 2033-2052

  Ferriz J M ^a   Vinsova J ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Biochemical pathways; Drug delivery; Phenolic functional group; Prodrug strategies

Indexed keywords

CARBAMIC ACID DERIVATIVE; CARBIDOPA PLUS LEVODOPA; CARBONIC ACID DERIVATIVE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; ENKEPHALIN DERIVATIVE; ENTACAPONE; EPOSIN; ESTER DERIVATIVE; ETHER DERIVATIVE; ETOPOFOS; ETOPOSIDE; FOSPROPOFOL; HYDROXYL GROUP; LUSEDRA; MEPTAZINOL; MIPROXIFENE PHOSPHATE; MORPHINE; NALBUPHINE; PA 2789; PA 2808; PARACETAMOL; PHENOL DERIVATIVE; PHOSPHATE; PRODRUG; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STILBENE DERIVATIVE; STILSTATIN 1; STILSTATIN 2; SULFATE; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; ESTERIFICATION; FIRST PASS EFFECT; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; NEOPLASMS; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PHENOLS; PRODRUGS;

EID: 77953529026     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791293042     Document Type: Article

References (124)

1. Silverman RB. The organic chemistry of drug design and drug action. Drug Metabolism. New York: Elsevier Academic Press 2004; pp. 405-98.
2. Georgie GF. Drug metabolism by the gastrointestinal mucosa. Clin Pharmacokinet 1981; 6: 259-74.
3. Testa B. Prodrug research: futile or fertile. Biochem Pharmacol 2004; 68: 2097-106.
4. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW. Prodrugs: Challenges and Rewards Part 1. New York: Springer Science-Business Media 2007.
5. Fleisher D, Bong R, Stewart BH. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv Drug Deliv Rev 1996; 19: 115-30.
6. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Deliver Rev 2007; 59: 677-94.
7. Charman WN, Porter CJH. Lipophilic prodrugs design for intestinal lymphatic transport. Adv Drug Deliver Rev 1996; 19: 149-69.
8. Anderson BD. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 1996; 19: 171-202.
9. Krishnamoorthy R, Mitra AK. Prodrugs for nasal drug delivery. Adv Drug Deliver Rev 1998; 29: 135-46.
10. Takakura Y, Hashida M. Macromolecular drug carrier system in cancer chemotherapy: macromolecular prodrugs. Crit Rev Oncol Hematol 1995; 18: 207-31.
11. Sinhababu AK, Thakker DR. Prodrugs of anticancer agents. Adv Drug Deliv Rev 1996; 19: 241-73.
12. Niculescu-Duvaz I, Springer CJ. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv Drug Deliv Rev 1997; 26: 151-72.
13. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem 2001; 36: 577-95.
14. Greenwald RB. PEG drugs: an overview. J Control Release 2001; 74: 159-71.
15. Johansen M, Bundgaard H. Prodrugs as drug delivery systems. XVI. Novel water-soluble prodrug types of chlozoxazone by esterification of the N-hydroxymethyl derivatives. Arch Pharm Chem Sci Edn 1981; 8: 43-54.
16. Beaumont K, Webster R, Gardner I, Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab 2003; 4: 461-85.
17. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 2006; 95: 1177-95.
18. Vin ová J, Imramovsk A. Intramolekulární cyklizace vyu ívané k uvol ovaní ú inn ch látek z prolé iv. Chem Listy 2005; 99: 21-9.
19. Gomes P, Vale N, Moreira R. Cyclization-activated prodrugs. Molecules 2007; 12: 2484-506.
20. Fredholt K, Mork N, Begtrup M. Hemiesters of aliphatic dicarboxylic acids as cyclization-activated prodrug forms for protecting phenols against first-pass metabolism. Int J Pharm 1995; 123: 209-16.
21. Santos C, Mateus ML, dos Santos AP, Moreira R, Oliveira E, Gomes P. Cyclization-activated prodrugs. Synthesis, reactivity and toxicity of dipeptide esters of paracetamol. Bioorg Med Chem Lett 2005; 15: 1595-8.
22. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behaviour after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990; 47: 12-9.
23. Christrup LL, Christensen CB, Trios GJ, Jorgensen A. Improvement of buccal delivery of morphine using the prodrug approach. Int J Pharm 1997; 154: 157-65.
24. Drustrup J, Fullerton A, Christup L, Bundgaard H. Utilization of prodrugs to enhance the transdermal absorption of morphine. Int J Pharm 1991; 71: 105-16.
25. Kawaguchi T, Fukushima S, Hayashi Y, Nakano M. Nonenzymatic and Enzymatic hydrolysis of 5-Fluoro-2́-deoxyuridine (FudR) esters. Pharm Res 1988; 5: 741-4.
26. Aungst BJ, Myers MJ, Shefter E, Shami EG. Prodrugs for improved oral nalbuphine bioavailability: inter-species differences in the disposition of nalbuphine and its acetylsalicylate and anthranilate esters. Int J Pharm 1987; 38: 199-209.
27. Norbury HM, Franklin RA, Graham DF. Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers. Eur J Clin Pharmacol 1983; 25: 77-80.
28. Lu M, Zhang C, Hao J, Qiu Z. Synthesis and relative bioavailability of meptazinol benzoyl esters as prodrugs. Bioorg Med Chem Lett 2005; 15: 2607-9.
29. Xie Q, Wang X, Wang X, Jiang Z, Qiu Z. Design, synthesis and bioavailability evaluation of coumarin-based prodrug of meptazinol. Bioorg Med Chem Lett 2005; 15: 4953-6.
30. Camenisch GP, Wang W, Wang B, Borchardt RT. A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics. Pharm Res 1998; 15: 1174-81.
31. Gudmundsson O, Pauletti GM, Wang W, Shan D, Zhan H, Wang B, et al. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability. Pharm Res 1999; 16: 7-15.
32. Wang W, Camenisch G, Sane DC, Zhang H, Hugger E, Wheeler GL, et al. A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimetics. J Control Release 2000; 65: 245-51.
33. Tang FX, Borchardt RT. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm Res 2002; 19: 787-93.
34. Zych LA, Yang WQ, Liao Y, Griffin KR, Wang B. The effect of substitution patterns on the release rates of opioid peptides DADLE and [Leu(5)]-enkephalin from coumarin prodrug moieties. Bioorg Chem 2004; 32: 109-23.
35. Prankerd RD, Stella VJ. Use of oil-in-water emulsions as a vehicle for parenteral drug administration. J Parent Sci Technol 1990; 44: 139-49.
36. Trapani G, Latrofa A, Franco M, Lopedota A, Maciocco E, Liso G. Water-soluble salts of aminoacids esters of the anaesthetic agent Propofol. Int J Pharm 1998; 175: 195-204.
37. Altomare C, Trapani G, Latrofa A, Serra M, Sanna E, Biggio G, et al. Highly water-soluble derivatives of the anesthetic agent propofol: in vitro and in vivo evaluation of cyclic amino acid esters. Eur J Pharm Sci 2003; 20: 17-26.
38. Humphrey MJ, Ringrose PS. Peptides and related drugs: a review of their absorption, metabolism and excretion. Drug Met Rev 1986; 17: 283-310.
39. Bundgaard H. Means to enhance penetration. Prodrugs as a means to improve the delivery of peptide drugs. Adv Drug Deliv Rev 1992; 8: 1-38.
40. Gangwar S, Pauletti GM, Wang B, Siahaan TJ, Stella VJ, Borchardt RT. Prodrugs strategies to enhance the intestinal absorption of peptides. Drug Discov Today 1997; 2: 148-55.
41. Oliyai R. Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv Drug Deliv Rev 1996; 19: 275-86.
42. Fredholt K, Adrian C, Just L, Larsen DH, Weng S, Moss B, et al. Chemical and enzymatic stability as well as transport properties of a Leu-enkephalin analogue and ester prodrugs thereof. J Control Release 2000; 63: 261-73.
43. Friedman DI, Amidon GL. Oral absorption of peptides: Influence of pH and inhibitors on the intestinal hydrolysis of Leu-enkephalin analogues. Pharm Res 1991; 8: 93-6.
44. Hartsuck J A, Lipscomb W N. In: Carboxypeptidase A, Boyer PD, Ed. The Enzymes. New York: Academic Press 1971; vol. 3: pp.1-56.
45. Boyer TD, Rouff SL. Acethaminophen-induced hepatic necrosis adrenal failure. J Am Med Assoc 1971; 218: 440-1.
46. Fadl TA, Omar FA. Paracetamol (Acetaminophen) esters of some non-esteroidal anti-inflammatory carboxylic acids as mutual prodrugs with improved therapeutic index. Inflammopharm 1998; 6: 143-57.
47. Goolcharran C, Borchardt RT. Kinetics of diketopiperazine formation using model peptides. J Pharm Sci 1998; 87: 283-8.
48. Santos C, Mateus ML, Santos AP, Moreira R, Oliviera E, Gomes P. Cyclization-activated prodrugs. Synthesis, reactivity and toxicity of dipeptide esters of paracetamol. Bioorg Med Chem Lett 2005; 15: 1595-8.
49. Safari M, Oliyai R, Stella VJ. Phosphoryloxymethyl carbamates and carbonates-novel water-soluble prodrugs for amines and hindered alcohols. Pharm Res 1993; 10: 1350-5.
50. Gani D, Wilkie J. Stereochemical, mechanistic and structural features of enzyme-catalyzed phosphate monoester hydrolyses. Chem Soc Rev 1995; 24: 55-63.
51. Banaszczyk MG, Carlo AT, Milan V, Lindsey A, Moss R, Carlo DJ, et al. Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. Anesth Analg 2002; 95: 1285-92.
52. Schywalsky M, Ihmsen H, Tzabazis A, Fechner J, Burak E, Vornov J, et al. Pharmacokinetics and pharmacodynamics of the new propofol gpi 15715 in rats. Eur J Anaesthesiol 2003; 20: 182-90.
53. Kumpulainen H, Järvinen T, Mannila A, Leppänen J, Nevalainen T, Mäntylä A, et al. Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol. Eur J Pharm Sci 2008; 34: 110-7.
54. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4. Experientia 1989; 45: 205-11.
55. Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin tumor inhibitor. Invest New Drug 1996; 14: 131-7.
56. Pettit GR, Minardi MD, Hogan F, Price PM. An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins. J Nat Prod 2010, in press, DOI: 10.1021/np9004486
57. Tozer MT, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MRL, et al. Cobretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999; 59: 1626-34.
58. Ducki S, Rennison D, Woo M, Kendall A, Chabert JFD, McGown AT, et al. NJ. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. Bioorg Med Chem 2009; 22: 7698-710.
59. Pettit GR, Thornhill A, Melody N, Knight JC. Antineoplastic Agents. 578. Synthesis of stilstatins 1 and 2 and their water-soluble prodrugs. J Nat Prod 2009; 72: 380-8.
60. Shirali A, Sriram M, Hall JJ, Nguyen BL, Guddneppanavar R, Hadimani MB, et al. Development of synthetic methodology suitable for the radiosynthesis of combretastatin A-1 (CA1) and its corresponding prodrug CA1P. J Nat Prod 2009; 72: 414-21.
61. Schacter L. Etoposide phosphate: what, why, where and how? Semin Oncol 1996; 23: 1-7.
62. Fields SZ, Igwemezie LN, Kaul S, Schacter LP, Schiller PP, Himpler BS, et al. Phase I Study of etoposide phosphate (Etopo-phos) as a 30-minute infusion on days 1, 3 and 5. Clin Cancer Res 1995; 1: 105-11.
63. Fields SZ, Budman DR, Young RR, Kreis W, Ingram R, Schulman P, et al. Phase I study of high-dose etoposide phosphate in man. Bone Marrow Transpl 1996; 18: 851-6.
64. Baker WR, Cai S, Dimitroff M, Fang L, Huh KK, Ryckman DR, et al. A prodrug approach toward the development of water soluble fluoroquinolones and structure-activity relationships of quinoline-3-carboxylic acids. J Med Chem 2004; 47: 4693-709.
65. Godden DJ, Borland C, Lowry R, Higenbottan TW. Chemical specificity of coughing in man. Clin Sci 1986; 70: 301-6.
66. Nomura Y, Abe O, Enomoto K, Fujiwara K, Tominaga T, Hayashi K, et al. Phase I Study of TAT-59 (a new antiestrogen) in breast cancer. Gan To Kagaku Ryoho 1998; 25: 553-61.
67. Nomura Y, Nakajima M, Tominaga T, Abe O. Late phase II Study of TAT-59 (miproxifene phosphate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate). Gan To Kagaku Ryoho 1998; 25: 1045-63.
68. Heimbach T, Oh DM, Li LY, Rodriguez-Hornedo N, Garcia G, Fleisher D. Enzyme-Mediated precipitation of parent drugs from their phosphate prodrugs. Int J Pharm 2003; 261: 81-92.
69. Heimbach T, Oh DM, Li L. Y, Forsberg M, Leppänen J, Matsunaga Y, et al. Absorption rate limit considerations for oral phosphate prodrugs. Pharm Res 2003; 20: 848-56.
70. Henchcliffe C, Waters C. Entacapone in the management of Parkinson's disease. Expert Opin Pharmacother 2002; 3: 957-63.
71. Savolain J, Forsberg M, Taipale H, Mannisto PT, Jarvinen K, Gynther J, et al. Effects of aqueous solubility and dissolution characteristics on oral bioavailability of entacapone. Drug Dev Res 2000; 49: 238-44.
72. Leppänen JM, Huuskonen J, Savolainen J, Nevalainen T, Taipale H, Vepsalainen J, et al. Synthesis of a water-soluble prodrug of entacapone. Bioorg Med Chem Lett 2000; 10: 1967-9.
73. Parish LC, Parish JL. Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections. Drugs Today (Barc) 2008; 44: 91-102.
74. Fu L; Jiang Z, Cai Z, Liu X, He H, Yang Y. Water-soluble phosphate prodrugs of pleuromutilin analogues with potent in vivo antibacterial activity against Gram-positive pathogens. Bioorg Med Chem Lett 2009; 19: 5407-10.
75. Hecker SJ, Erion MD. Prodrugs of phosphates and phosphonates. J Med Chem 2008; 51: 2328-45.
76. Hansen J, Mork N, Bundgaard H. Phenyl carbamates of amino acids as prodrug forms for protecting phenols against first-pass metabolism. Int J Pharm 1992; 81: 253-61.
77. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW. Prodrugs. Challenges and rewards Part 2. New York: Springer Science-Business Media 2007; p. 54.
78. Thomsen KF, Bundgaard H. Cyclization-activated phenyl carbamate prodrug forms for protecting phenols against first-pass metabolism. Int J Pharm 1993; 91: 39-49.
79. Hansen KT, Jansen JA, Mengel H, Christensen JV, Bundgaard H. Enhanced bioavailability of a new class of dopamine-D-1 antagonists following oral administration of their carbamic acid ester prodrugs to dogs. Int J Pharm 1992; 79: 205-12.
80. Savolainen J, Leppänen J, Forsberg M, Taipale H, Nevalainen T, Huuskonen J, et al. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl and N,N-dialkyl-carbamate esters of entacapone. Life Sci 2000; 67: 205-16.
81. Nilsson JLG, Carlsson A. Dopamine-receptor agonist with apparent selectivity for autoreceptors: a new principle for antipsychotic action? Trends Pharmacol Sci 1981; 3: 322-5.
82. Thorberg SO, Berg S, Lundström J, Petterson B, Wijkström A, Sanchez D, et al. Carbamates ester derivatives as potencial prodrugs of the presynaptic dopamine autoreceptor agonist (-)-3-(hydroxyphenyl)-N-propylpiperidine. J Med Chem 1987; 30: 2008-12.
83. Nyberg L. Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis 1984; 134: 149-60.
84. Olsson T, Svensson LÅ. New lipophilic terbutaline ester prodrugs with long effect duration. Pharm Res 1984; 1: 19-23.
85. Svensson LÅ, Tunek A. The design and bioactivation of the presystemically stable prodrugs. Pharm Res 1988; 19: 165-94.
86. Igarashi Y, Yanagisawa E, Ohshima T, Takeda S, Aburada M, Miyamoto KI. Synthesis and evaluation of carbamate prodrugs of a phenolic compound. Chem Pharm Bull 2007; 55: 328-33.
87. Muther RS, Bennet WM. Effects of dimethyl sulfoxide on renal function in man. JAMA 1980; 244: 2081-3.
88. Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacolo-gical, cellular and molecular aspects. Biochem Pharmacol 2003; 65: 1035-41.
89. Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, et al. Pre-clinical and clinical study of Qc12, a water-soluble prodrug of quercetin. Ann Oncol 2001; 12: 245-8.
90. Kim MK, Park KS, Yeo WS, Choo H, Chong Y. In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. Bioorg Med Chem 2009; 17: 1164-71.
91. Frei E. III Curative cancer chemotherapy. Cancer Res 1985; 45: 6532-8.
92. Kapuriya N, Kapuriya K, Dong H, Zhang X, Chou TC, Chen YT, et al. Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridinine conjugates via a carbamate or carbonate linker. Bioorg Med Chem 2009; 17: 1264-75.
93. Springer CJ, Dowell R, Burke PJ, Hadley E, Davies DH, Blakey DC, et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 1995; 38: 5051-65.
94. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW. Prodrugs: challenges and rewards Part 2. New York: Springer Science-Business Media 2007; p. 56.
95. Verma RP, Hansch C. Camptothecins: a SAR/QSAR study. Chem Rev 2009; 109: 213-35.
96. Wang Y, Li L, Jiang W, Larrick JW. Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg Med Chem 2005; 13: 5592-9.
97. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944-7.
98. Schmidt F, Monneret C. Prodrug mono therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug. Bioorg Med Chem 2003; 11: 2277-83.
99. Bosslet K, Strub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998; 57: 1195-201.
100. de Groot FMH, Damen EWP, Scheeren HW. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr Med Chem 2001; 8: 1093-122.
101. Yoon KJ, Qi J, Remack JS, Virga KG, Hatfield MJ, Potter PM, et al. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. Mol Cancer Ther 2006; 5: 1577.
102. Stern L, Perry R, Ofek P, Many A, Shabat D, Satchi-Fainaro R. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. Bioconjugate Chem 2009; 20: 500-10.
103. Wang Y, Li L, Tian Z, Jiang W, Larrick JW. Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue. Bioorg Med Chem 2006; 14: 7854-61
104. Vaddi HK, Banks SL, Chen J, Hammell DC, Crooks PA. Human skin permeation of 3-O-alkyl carbamate prodrugs of Naltrexone. J Pharm Sci 2009; 98: 2611-25.
105. Ray S, Chaturvedi D. Application of organic carbamates in drug design. Part 1: anticancer agents -recent reports. Drug Fut 2004; 29: 343-57.
106. Lobo RA, Cassident DL. Pharmacokinetics of oral 17b-estradiol. J Reprod Med 1992; 37: 77-84.
107. Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Biol 1995; 55: 395-403.
108. Bauer K, Elger W, Schneider B, Krahl E, Buer R. Effect of estradiol sulphamate (ES-J995) on affinity of haemoglobin for oxygen, cardiovascular function and acid-base balance in ovariectomized rats. Exp Toxic Pathol 2003; 55: 301-7.
109. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW. Prodrugs: challenges and rewards Part 2. New York: Springer Science-Business Media 2007; p. 59.
110. Getz JJ, Prankerd RJ, Sloan KB. Mechanism of hydrolysis of O-imidomethyl derivatives of phenols. J Org Chem 1993; 58: 4913-8.
111. Patel JU, Prankerd RJ, Sloan KB. A prodrug approach to increasing the oral potency of a phenolic drug. Part 1. Synthesis, caracterization and stability of an O-(imidomethyl) derivative of 17 -estradiol. J Pharm Sci 1994; 83: 1477-81.
112. Longcope C, Gorbach S, Goldin B, Woods MJ, Dwyer J, Warram J. The metabolism of estradiol-Oral compared to intravenous administration. J Steroid Biochem 1985; 23: 1065-70.
113. Patel J, Katovich MJ, Sloan KB, Curry SH, Pranker RJ. A prodrug approach to increasing the oral potency of a phenolic drug. Part 2. Pharmacodynamics and preliminary bioavailability of an orally administered O-(iodomethyl) derivative of 17 -estradiol. J Pharm Sci 1994; 84: 174-8.
114. Fenández C, Nieto O, Rival E, Montenegro G, Fontenla JA, Fernández-Mayoralas A. Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohidr Res 2000; 327: 353-65.
115. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994; 219: 713-25.
116. Fernández C, Nieto O, Fontenla JA, Rivas MLC, Fernández-Mayoralas A. Synthesis of glycosyl derivatives as dopamine pro-drugs: interaction with glucose carrier GLUT-1. Org Biomol Chem 2003; 1: 767-71.
117. Leu LY, Chen CS, Yih-Jang Wu YJ, Chern JW. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. J Med Chem 2008; 51: 1740-6.
118. Majumdar S, Sloan KB. Synthesis and topical delivery of N-alkyloxycarbonylaminomethyl prodrugs of a model phenolic drug: acetaminophen. Int J Pharm 2007; 337: 48-55.
119. Wasdo S, Sloan KB. Topical delivery of a model phenolic drug: alkyoxycarbonyl prodrugs of acetaminophen. Pharm Res 2004; 21: 940-6.
120. Thomas JD, Sloan KB. In vitro evaluation of alkylcarbonyloxy-methyl (ACOM) ethers as novel prodrugs of phenols for topical delivery: ACOM prodrugs of acetaminophen. Int J Pharm 2008; 346: 80-8.
121. Orienti I, Zuccari G, Bergamante V, Carosio R, Gotti R, Cilli M, et al. Fenretinide-polyvinylalcohol conjugates: New systems alowing fenretinide itravenous aministration. Biomacromolecules 2007; 8: 3258-62.
122. Ostergaard J, Larsen C. Bioreversible derivatives of phenol.2. Reactivity of carbonate esters with fatty acid-like structures towards hydrolysis in aqueous solutions. Molecules 2007; 12: 2396-412.
123. Ostergaard J, Larsen C. Bioreversible derivatives of phenol. 1. The role of human serum albumin as related to the stability and binding properties of carbonate esters with fatty acids-like structures in aqueous solution and biological media. Molecules 2007; 12: 2380-95.
124. Thomas JD, Sloan KB. Evaluation of alkyloxycarbonyloxymethyl (AOCOM) ethers as novel prodrugs of phenols for topical delivery: AOCOM prodrugs of acetaminophen. Int J Pharm 2009; 371: 25-32.